Back to search

Peptide record

TPDB07291

Indolicidin Indolocidin-ac Antibacterial Anticancer Antifungal Antiparasitic Antiviral Cell-penetrating Peptides Hemolysis Toxicity standard
13 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB07291
Indolicidin Indolocidin-ac
Antibacterial Anticancer Antifungal Antiparasitic Antiviral Cell-penetrating Peptides Hemolysis Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides Delivery and barrier-penetrating peptides
AntiBP3 dbAMP DRAMP Peptipedia ACP740 _ACP240 AntiCP 2.0 CancerPPD 2.0 SATPdb dbACP iACP-DRLF AFP-GFuse Antifungipept CAFPdb dbAMP 3.0 i2APP AI4AVP AVPpred-BWR DRAVP 2.0 CPPsite3.0 APD_complete APD_hemolytic HemoPI Hemolytic2 PD_Hemolysis ToxinPred 3.0
standard
No
A 13-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.
Sequence
ILPWKWPWWPWRR
Physicochemical Analysis
C100H131N25O14
ANDCEQGHMFSTYV
W
1907.30
12.41
3
0
7
+3
-6.16
-1.069
60.00
Mammalian: 20 hour Yeast: 30 min E.coli: >10 hour
27500
1441.83
0
Residue Composition
number
0
A
2
R
0
N
0
D
0
C
0
E
0
Q
0
G
0
H
1
I
1
L
1
K
0
M
0
F
3
P
0
S
0
T
5
W
0
Y
0
V
Amino Acid Distribution
A: 0 R: 2 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 1 L: 1 K: 1 M: 0 F: 0 P: 3 S: 0 T: 0 W: 5 Y: 0 V: 0
Chemical Descriptors
13
C100H131N25O14
1907.30
12.41
+3
-6.16
-1.069
Free
L
Cationic
Linear
Linear
Free
Anticancer
FLAK peptides
N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=C(C(=NC1)C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=C(C(=NC1)C)CC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=C(C(=NC1)C)CC)C(=O)N[C@@H](CC1=C(C(=NC1)C)CC)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC1=CN=C(C)/C/1=C\C)C(=O)N[C@@H](CCCN=C)C(=O)N[C@@H](CCCN=C)C(=O)O
Evidence Records 53 records
Evidence 1 Activity

Activity

MIC
Antibacterial
1.5-3 µM

Target

Staphylococcus aureus ATCC29213 or NCDC-0111 or MRSA

Source & Reference

dbAMP DRAMP

Other

Source Activity Label Source Definition
Antibacterial
dbAMP classified as Antibacterial under the Anti-bacterial function class. DRAMP antibacterial activity supported by MIC records against bacterial target organisms.
Active against S. aureus ATCC29213 or NCDC-0111 or MRSA (MIC 1.5-3 uM), L. monocytogenes ATCC-19111 (MIC 6 uM), B. cereus NCDC-0240 (MIC 0.8 uM), P. aeruginosa
Evidence 2 Activity

Activity

MIC
Antibacterial
6 µM

Target

L. monocytogenes ATCC-19111

Source & Reference

dbAMP DRAMP

Other

Active against S. aureus ATCC29213 or NCDC-0111 or MRSA (MIC 1.5-3 uM), L. monocytogenes ATCC-19111 (MIC 6 uM), B. cereus NCDC-0240 (MIC 0.8 uM), P. aeruginosa ATCC-27853 or NCDC-0105 (MIC 12.5-25 uM)
Evidence 3 Activity

Activity

MIC
Antibacterial
0.8 µM

Target

B. cereus NCDC-0240

Source & Reference

dbAMP DRAMP

Other

us ATCC29213 or NCDC-0111 or MRSA (MIC 1.5-3 uM), L. monocytogenes ATCC-19111 (MIC 6 uM), B. cereus NCDC-0240 (MIC 0.8 uM), P. aeruginosa ATCC-27853 or NCDC-0105 (MIC 12.5-25 uM), S. enterica serovar typhimurium
Evidence 4 Activity

Activity

MIC
Antibacterial
12.5-25 µM

Target

Pseudomonas aeruginosa ATCC-27853 or NCDC-0105

Source & Reference

dbAMP DRAMP

Other

(MIC 1.5-3 uM), L. monocytogenes ATCC-19111 (MIC 6 uM), B. cereus NCDC-0240 (MIC 0.8 uM), P. aeruginosa ATCC-27853 or NCDC-0105 (MIC 12.5-25 uM), S. enterica serovar typhimurium ATCC-14028 (MIC 12.5 uM), E. coli MTCC-0723 (MIC 0.8 uM)
Evidence 5 Activity

Activity

MIC
Antibacterial
12.5 µM

Target

S. enterica serovar typhimurium ATCC-14028

Source & Reference

dbAMP DRAMP

Other

B. cereus NCDC-0240 (MIC 0.8 uM), P. aeruginosa ATCC-27853 or NCDC-0105 (MIC 12.5-25 uM), S. enterica serovar typhimurium ATCC-14028 (MIC 12.5 uM), E. coli MTCC-0723 (MIC 0.8 uM), and A. johnsonii NCDC-0072 (MIC 6 uM) ( Brahma B et al.,
Evidence 6 Activity

Activity

MIC
Antibacterial
0.8 µM

Target

Escherichia coli MTCC-0723

Source & Reference

dbAMP DRAMP

Other

or NCDC-0105 (MIC 12.5-25 uM), S. enterica serovar typhimurium ATCC-14028 (MIC 12.5 uM), E. coli MTCC-0723 (MIC 0.8 uM), and A. johnsonii NCDC-0072 (MIC 6 uM) ( Brahma B et al., 2015 ). Also active against Her
Evidence 7 Activity

Activity

MIC
Antibacterial
6 µM

Target

A. johnsonii NCDC-0072

Source & Reference

dbAMP DRAMP

Other

nterica serovar typhimurium ATCC-14028 (MIC 12.5 uM), E. coli MTCC-0723 (MIC 0.8 uM), and A. johnsonii NCDC-0072 (MIC 6 uM) ( Brahma B et al., 2015 ). Also active against Herpes Simplex Virus (HSV-1 and HSV-2) ( Y
Evidence 8 Activity

Activity

LD50
LD50 =12 µg/ml
Anticancer
12 µg/mL

Target

Breast Cancer
MCF-7
Breast

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005
US_06875744_B2

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation. dbAMP 3.0 classified as Anticancer under the disease-associated peptide function classes.
Evidence 9 Activity

Activity

LD50
LD50 =30 µg/ml
Anticancer
30 µg/mL

Target

Colon Cancer
SW-480
Colon

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 10 Activity

Activity

LD50
LD50 =180 µg/ml
Anticancer
180 µg/mL

Target

Skin Cancer
BMKC
Skin

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 11 Activity

Activity

LD50
LD50 =64 µg/ml
Anticancer
64 µg/mL

Target

Lung Cancer
H-1299
Lung

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 12 Activity

Activity

LD50
LD50 =31 µg/ml
Anticancer
31 µg/mL

Target

Prostate Cancer
PC-3
Prostate

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 13 Activity

Activity

LD50
LD50 =20 µg/ml
Anticancer
20 µg/mL

Target

Cervical Cancer
HeLa
Cervix

Assay & Model

MTT/MTS assay
24-h

Source & Reference

dbAMP 3.0 CancerPPD 2.0 dbACP SATPdb
CancerPPD2
2005
US_06875744_B2
Evidence 14 Activity

Activity

MIC
Antifungal
1.5-3 µM

Target

Staphylococcus aureus ATCC29213 or NCDC-0111 or MRSA

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Source Activity Label Source Definition
Antifungal
dbAMP classified under the Anti-fungal function class. DRAMP antifungal activity supported by activity records against fungal target organisms.
Active against S. aureus ATCC29213 or NCDC-0111 or MRSA (MIC 1.5-3 uM), L. monocytogenes ATCC-19111 (MIC 6 uM), B. cereus NCDC-0240 (MIC 0.8 uM), P. aeruginosa
Evidence 15 Activity

Activity

MIC
Antifungal
6 µM

Target

L. monocytogenes ATCC-19111

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

Active against S. aureus ATCC29213 or NCDC-0111 or MRSA (MIC 1.5-3 uM), L. monocytogenes ATCC-19111 (MIC 6 uM), B. cereus NCDC-0240 (MIC 0.8 uM), P. aeruginosa ATCC-27853 or NCDC-0105 (MIC 12.5-25 uM)
Evidence 16 Activity

Activity

MIC
Antifungal
0.8 µM

Target

B. cereus NCDC-0240

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

us ATCC29213 or NCDC-0111 or MRSA (MIC 1.5-3 uM), L. monocytogenes ATCC-19111 (MIC 6 uM), B. cereus NCDC-0240 (MIC 0.8 uM), P. aeruginosa ATCC-27853 or NCDC-0105 (MIC 12.5-25 uM), S. enterica serovar typhimurium
Evidence 17 Activity

Activity

MIC
Antifungal
12.5-25 µM

Target

Pseudomonas aeruginosa ATCC-27853 or NCDC-0105

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

(MIC 1.5-3 uM), L. monocytogenes ATCC-19111 (MIC 6 uM), B. cereus NCDC-0240 (MIC 0.8 uM), P. aeruginosa ATCC-27853 or NCDC-0105 (MIC 12.5-25 uM), S. enterica serovar typhimurium ATCC-14028 (MIC 12.5 uM), E. coli MTCC-0723 (MIC 0.8 uM)
Evidence 18 Activity

Activity

MIC
Antifungal
12.5 µM

Target

S. enterica serovar typhimurium ATCC-14028

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

B. cereus NCDC-0240 (MIC 0.8 uM), P. aeruginosa ATCC-27853 or NCDC-0105 (MIC 12.5-25 uM), S. enterica serovar typhimurium ATCC-14028 (MIC 12.5 uM), E. coli MTCC-0723 (MIC 0.8 uM), and A. johnsonii NCDC-0072 (MIC 6 uM) ( Brahma B et al.,
Evidence 19 Activity

Activity

MIC
Antifungal
0.8 µM

Target

Escherichia coli MTCC-0723

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

or NCDC-0105 (MIC 12.5-25 uM), S. enterica serovar typhimurium ATCC-14028 (MIC 12.5 uM), E. coli MTCC-0723 (MIC 0.8 uM), and A. johnsonii NCDC-0072 (MIC 6 uM) ( Brahma B et al., 2015 ). Also active against Her
Evidence 20 Activity

Activity

MIC
Antifungal
6 µM

Target

A. johnsonii NCDC-0072

Source & Reference

dbAMP DRAMP CAFPdb Antifungipept

Other

nterica serovar typhimurium ATCC-14028 (MIC 12.5 uM), E. coli MTCC-0723 (MIC 0.8 uM), and A. johnsonii NCDC-0072 (MIC 6 uM) ( Brahma B et al., 2015 ). Also active against Herpes Simplex Virus (HSV-1 and HSV-2) ( Y
Evidence 21 Activity

Activity

MIC
Antiparasitic
1.5-3 µM

Target

Staphylococcus aureus ATCC29213 or NCDC-0111 or MRSA

Source & Reference

dbAMP 3.0 DRAMP

Other

Source Activity Label Source Definition
Antiparasitic
DRAMP antiparasitic activity supported by activity records against parasitic targets. dbAMP 3.0 classified under the Anti-parasitic function class.
Active against S. aureus ATCC29213 or NCDC-0111 or MRSA (MIC 1.5-3 uM), L. monocytogenes ATCC-19111 (MIC 6 uM), B. cereus NCDC-0240 (MIC 0.8 uM), P. aeruginosa
Evidence 22 Activity

Activity

MIC
Antiparasitic
6 µM

Target

L. monocytogenes ATCC-19111

Source & Reference

dbAMP 3.0 DRAMP

Other

Active against S. aureus ATCC29213 or NCDC-0111 or MRSA (MIC 1.5-3 uM), L. monocytogenes ATCC-19111 (MIC 6 uM), B. cereus NCDC-0240 (MIC 0.8 uM), P. aeruginosa ATCC-27853 or NCDC-0105 (MIC 12.5-25 uM)
Evidence 23 Activity

Activity

MIC
Antiparasitic
0.8 µM

Target

B. cereus NCDC-0240

Source & Reference

dbAMP 3.0 DRAMP

Other

us ATCC29213 or NCDC-0111 or MRSA (MIC 1.5-3 uM), L. monocytogenes ATCC-19111 (MIC 6 uM), B. cereus NCDC-0240 (MIC 0.8 uM), P. aeruginosa ATCC-27853 or NCDC-0105 (MIC 12.5-25 uM), S. enterica serovar typhimurium
Evidence 24 Activity

Activity

MIC
Antiparasitic
12.5-25 µM

Target

Pseudomonas aeruginosa ATCC-27853 or NCDC-0105

Source & Reference

dbAMP 3.0 DRAMP

Other

(MIC 1.5-3 uM), L. monocytogenes ATCC-19111 (MIC 6 uM), B. cereus NCDC-0240 (MIC 0.8 uM), P. aeruginosa ATCC-27853 or NCDC-0105 (MIC 12.5-25 uM), S. enterica serovar typhimurium ATCC-14028 (MIC 12.5 uM), E. coli MTCC-0723 (MIC 0.8 uM)
Evidence 25 Activity

Activity

MIC
Antiparasitic
12.5 µM

Target

S. enterica serovar typhimurium ATCC-14028

Source & Reference

dbAMP 3.0 DRAMP

Other

B. cereus NCDC-0240 (MIC 0.8 uM), P. aeruginosa ATCC-27853 or NCDC-0105 (MIC 12.5-25 uM), S. enterica serovar typhimurium ATCC-14028 (MIC 12.5 uM), E. coli MTCC-0723 (MIC 0.8 uM), and A. johnsonii NCDC-0072 (MIC 6 uM) ( Brahma B et al.,
Evidence 26 Activity

Activity

MIC
Antiparasitic
0.8 µM

Target

Escherichia coli MTCC-0723

Source & Reference

dbAMP 3.0 DRAMP

Other

or NCDC-0105 (MIC 12.5-25 uM), S. enterica serovar typhimurium ATCC-14028 (MIC 12.5 uM), E. coli MTCC-0723 (MIC 0.8 uM), and A. johnsonii NCDC-0072 (MIC 6 uM) ( Brahma B et al., 2015 ). Also active against Her
Evidence 27 Activity

Activity

MIC
Antiparasitic
6 µM

Target

A. johnsonii NCDC-0072

Source & Reference

dbAMP 3.0 DRAMP

Other

nterica serovar typhimurium ATCC-14028 (MIC 12.5 uM), E. coli MTCC-0723 (MIC 0.8 uM), and A. johnsonii NCDC-0072 (MIC 6 uM) ( Brahma B et al., 2015 ). Also active against Herpes Simplex Virus (HSV-1 and HSV-2) ( Y
Evidence 28 Activity

Activity

MIC
Antiviral
1.5-3 µM

Target

Staphylococcus aureus ATCC29213 or NCDC-0111 or MRSA

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

Source Activity Label Source Definition
Antiviral
DRAMP antiviral activity supported by activity records against viral targets. dbAMP 3.0 classified under the Anti-viral function class.
Active against S. aureus ATCC29213 or NCDC-0111 or MRSA (MIC 1.5-3 uM), L. monocytogenes ATCC-19111 (MIC 6 uM), B. cereus NCDC-0240 (MIC 0.8 uM), P. aeruginosa
Evidence 29 Activity

Activity

MIC
Antiviral
6 µM

Target

L. monocytogenes ATCC-19111

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

Active against S. aureus ATCC29213 or NCDC-0111 or MRSA (MIC 1.5-3 uM), L. monocytogenes ATCC-19111 (MIC 6 uM), B. cereus NCDC-0240 (MIC 0.8 uM), P. aeruginosa ATCC-27853 or NCDC-0105 (MIC 12.5-25 uM)
Evidence 30 Activity

Activity

MIC
Antiviral
0.8 µM

Target

B. cereus NCDC-0240

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

us ATCC29213 or NCDC-0111 or MRSA (MIC 1.5-3 uM), L. monocytogenes ATCC-19111 (MIC 6 uM), B. cereus NCDC-0240 (MIC 0.8 uM), P. aeruginosa ATCC-27853 or NCDC-0105 (MIC 12.5-25 uM), S. enterica serovar typhimurium
Evidence 31 Activity

Activity

MIC
Antiviral
12.5-25 µM

Target

Pseudomonas aeruginosa ATCC-27853 or NCDC-0105

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

(MIC 1.5-3 uM), L. monocytogenes ATCC-19111 (MIC 6 uM), B. cereus NCDC-0240 (MIC 0.8 uM), P. aeruginosa ATCC-27853 or NCDC-0105 (MIC 12.5-25 uM), S. enterica serovar typhimurium ATCC-14028 (MIC 12.5 uM), E. coli MTCC-0723 (MIC 0.8 uM)
Evidence 32 Activity

Activity

MIC
Antiviral
12.5 µM

Target

S. enterica serovar typhimurium ATCC-14028

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

B. cereus NCDC-0240 (MIC 0.8 uM), P. aeruginosa ATCC-27853 or NCDC-0105 (MIC 12.5-25 uM), S. enterica serovar typhimurium ATCC-14028 (MIC 12.5 uM), E. coli MTCC-0723 (MIC 0.8 uM), and A. johnsonii NCDC-0072 (MIC 6 uM) ( Brahma B et al.,
Evidence 33 Activity

Activity

MIC
Antiviral
0.8 µM

Target

Escherichia coli MTCC-0723

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

or NCDC-0105 (MIC 12.5-25 uM), S. enterica serovar typhimurium ATCC-14028 (MIC 12.5 uM), E. coli MTCC-0723 (MIC 0.8 uM), and A. johnsonii NCDC-0072 (MIC 6 uM) ( Brahma B et al., 2015 ). Also active against Her
Evidence 34 Activity

Activity

MIC
Antiviral
6 µM

Target

A. johnsonii NCDC-0072

Source & Reference

dbAMP 3.0 DRAMP DRAVP 2.0

Other

nterica serovar typhimurium ATCC-14028 (MIC 12.5 uM), E. coli MTCC-0723 (MIC 0.8 uM), and A. johnsonii NCDC-0072 (MIC 6 uM) ( Brahma B et al., 2015 ). Also active against Herpes Simplex Virus (HSV-1 and HSV-2) ( Y
Evidence 35 Activity

Activity

Cell-penetrating Peptides

Target

HeLa Cells

Source & Reference

CPPsite3.0
CPPsite3

Other

Source Activity Label Source Definition
Cell-penetrating Peptides
CPPsite3.0 experimentally validated cell-penetrating peptide annotation.
Natural residues Linear L Cationic
Protein derived
EGFP protein
Cytoplasm
EGFP‐CAT 2‐8‐times higher intensity than other derivative and 3‐6 times higher than EGFP‐LL37, EGFP‐IL, EGFP‐L‐K6, and EGFP‐TAT
In vitro
CCCCCCSCCCTTC
Evidence 36 Activity

Activity

100% Hemolysis
Toxicity
15.6 µM
Hemolytic Cytotoxic
100% Hemolysis | 15.6 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Structure-function relationships in the tryptophan-rich, antimicrobial peptide indolicidin. | J Pept Sci | 2001
Evidence 37 Activity

Activity

38% Hemolysis
Toxicity
80 µg/mL
Hemolytic Cytotoxic
38% Hemolysis | 80 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Evaluation of the inactivation of infectious Herpes simplex virus by host-defense peptides. | Eur J Clin Microbiol Infect Dis | 2000
Evidence 38 Activity

Activity

50% Hemolysis
Toxicity
40 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 40 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Short bioactive peptides | PATENT US 6875744B2 | 2005
Evidence 39 Activity

Activity

LD50
Toxicity
9 µg/mL
Cytotoxic
LD50 | 9 | µg/mL | target cell: Human fibroblasts WI-38

Target

Human fibroblasts WI-38

Source & Reference

NA
DBAASP
Short bioactive peptides | PATENT US 6875744B2 | 2005
Evidence 40 Activity

Activity

5% Hemolysis
Toxicity
50 µg/mL
Hemolytic Cytotoxic
5% Hemolysis | 50 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Investigating the effects of positive charge and hydrophobicity on the cell selectivity, mechanism of action and anti-inflammatory activity of a Trp-rich antimicrobial peptide indolicidin | FEMS Microbiol Lett | 2009
Evidence 41 Activity

Activity

50% Hemolysis
Toxicity
254 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 254 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Design of novel indolicidin-derived antimicrobial peptides with enhanced cell specificity and potent anti-inflammatory activity | Peptides | 2009
Evidence 42 Activity

Activity

35% Hemolysis
Toxicity
100 µg/mL
Hemolytic Cytotoxic
35% Hemolysis | 100 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Conformation-dependent antibiotic activity of tritrpticin, a cathelicidin-derived antimicrobial peptide | Biochem Biophys Res Commun | 2002
Evidence 43 Activity

Activity

100% Hemolysis
Toxicity
100 µg/mL
Hemolytic Cytotoxic
100% Hemolysis | 100 | µg/mL | target cell: Rat erythrocytes

Target

Rat erythrocytes

Source & Reference

NA
DBAASP
Antibacterial and hemolytic activities of single tryptophan analogs of indolicidin. | Biochem Biophys Res Commun | 2000
Evidence 44 Activity

Activity

23% Hemolysis
Toxicity
15 µM
Hemolytic Cytotoxic
23% Hemolysis | 15 | µM | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Broad-spectrum antimicrobial peptides by rational combinatorial design and high-throughput screening: the importance of interfacial activity | J Am Chem Soc | 2009
Evidence 45 Activity

Activity

4% Hemolysis
Toxicity
15 µM
Hemolytic Cytotoxic
4% Hemolysis | 15 | µM | target cell: Sheep erythrocytes

Target

Sheep erythrocytes

Source & Reference

NA
DBAASP
Broad-spectrum antimicrobial peptides by rational combinatorial design and high-throughput screening: the importance of interfacial activity | J Am Chem Soc | 2009
Evidence 46 Activity

Activity

56.98% Hemolysis
Toxicity
250 µg/mL
Hemolytic Cytotoxic
56.98% Hemolysis | 250 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Antimicrobial Activity of Novel Synthetic Peptides Derived from Indolicidin and Ranalexin against Streptococcus pneumoniae | PLoS One | 2015
Evidence 47 Activity

Activity

Toxicity
Cytotoxic
NA | target cell: Human lung normal epithelial cells NL20

Target

Human lung normal epithelial cells NL20

Source & Reference

NA
DBAASP
Antimicrobial Activity of Novel Synthetic Peptides Derived from Indolicidin and Ranalexin against Streptococcus pneumoniae | PLoS One | 2015
Evidence 48 Activity

Activity

10% Hemolysis
Toxicity
64 µg/mL
Hemolytic Cytotoxic
10% Hemolysis | 64 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Structure-activity relationship study of novel peptoids that mimic the structure of antimicrobial peptides. | Antimicrob Agents Chemother | 2015
Evidence 49 Activity

Activity

5% Hemolysis
Toxicity
25 µM
Hemolytic Cytotoxic
5% Hemolysis | 25 | µM | target cell: Rat erythrocytes

Target

Rat erythrocytes

Source & Reference

NA
DBAASP
Design of therapeutically improved analogue of the antimicrobial peptide, indolicidin, using a glycosylation strategy. | Amino Acids | 2019
Evidence 50 Activity

Activity

LD50
Toxicity
11 µM
Cytotoxic
LD50 | 11 | µM | target cell: Murine macrophage cells J774A.1

Target

Murine macrophage cells J774A.1

Source & Reference

NA
DBAASP
Design of therapeutically improved analogue of the antimicrobial peptide, indolicidin, using a glycosylation strategy. | Amino Acids | 2019
Evidence 51 Activity

Activity

50% Cytotoxicity
Toxicity
603 µg/mL
Cytotoxic
50% Cytotoxicity | 603 | µg/mL | target cell: Swine testis cells ST

Target

Swine testis cells ST

Source & Reference

NA
DBAASP
Antiviral effects of Bovine antimicrobial peptide against TGEV in vivo and in vitro. | J Vet Sci | 2020
Evidence 52 Activity

Activity

50% Hemolysis
Toxicity
166.7±25.82 µg/mL
Hemolytic Cytotoxic
50% Hemolysis | 166.7±25.82 | µg/mL | target cell: Human erythrocytes

Target

Human erythrocytes

Source & Reference

NA
DBAASP
Indolicidin analogs with broad-spectrum antimicrobial activity and low hemolytic activity | Peptides | 2020
Evidence 53 Hemolysis

Source & Reference

APD_complete APD_hemolytic HemoPI PD_Hemolysis
APD_complete APD_hemolytic PD_Hemolysis

Other

Source Activity Label Source Definition
Hemolysis
APD_complete APD-derived hemolytic peptide annotation. APD_hemolytic APD hemolytic peptide annotation.
Additional Detail Fields 1 fields
CCCCCCSCCCTTC